RNAC
NASDAQ
US
Cartesian Therapeutics, Inc. - Common Stock
$6.26
▼ $-0.13
(-2.03%)
Vol 60K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$187.5M
ROE
-3215.8%
Margin
-2489.8%
D/E
0.00
Beta
0.49
52W
$6–$20
Wall Street Consensus
15 analysts · Apr 20265
Strong Buy
7
Buy
3
Hold
0
Sell
0
Strong Sell
80.0%
Buy Rating
Price Chart
Similar Stocks
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
CNTB
Connect Biopharma Holdings Ltd
$157.6M
PRLD
Prelude Therapeutics Inc
$164.2M
ARTV
Artiva Biotherapeutics Inc
$105.3M
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
ABOS
Acumen Pharmaceuticals Inc
$127.8M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
Earnings
Beat rate: 50.0%
Next Report
May 06, 2026
EPS Estimate: $-0.90
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.90 | — | — |
| Dec 2025 | $-0.87 | $-3.57 | $-2.70 |
| Sep 2025 | $-0.86 | $-1.38 | $-0.52 |
| Jun 2025 | $-0.83 | $0.50 | +$1.33 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -3215.8% | -3215.8% | -3215.8% | -3215.8% | -3215.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 5330.9% | -1947.4% | -1947.4% | -1947.4% | -2489.8% | -2489.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 13.33 | 13.33 | 13.33 | 13.33 | 10.67 | 10.67 |
Key Ratios
ROA (TTM)
-12.0%
P/S (TTM)
97.29
P/B
2.2
EPS (TTM)
$-1.87
CF/Share
$-0.23
Rev Growth 3Y
-23.0%
52W High
$20.30
52W Low
$5.98
$5.98
52-Week Range
$20.30
How does RNAC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RNAC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
97.3
▲
657%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.2
▼
12%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RNAC profitability vs Biotechnology peers
ROE
-3215.8%
▼
4678%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-2489.8%
▼
768%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-12.0%
▲
74%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
RNAC financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
10.7
▲
140%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.5
▼
50%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
RNAC fundamentals radar
RNAC
Peer median
Industry
RNAC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio